Surveillance for multi-drug and rifampicin resistant tuberculosis and treatment outcomes among previously treated persons with tuberculosis in the era of GeneXpert in rural eastern Uganda.

J Clin Tuberc Other Mycobact Dis · 2020 · PMC7038458 · PMID 32123755

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Although the unadjusted analysis (RR, 2.29; 95% CI, 1.00–5.00) was borderline significant, there was no significant difference in MDR/RR-TB surveillance between health facilities with and without GeneXpert (aRR, 1.52; 95% CI, 0.81–2.86) at the adjusted analysis.

also in 11,409 other papers

showed a trendno p-value reported

MDR/RR-TB surveillance showed a trend towards a path of improvement over the three year period that the data were collected.

also in 53,322 other papers

an increasing trendno p-value reported

Treatment failures were less likely to have surveillance compared to relapses (aRR, 0.28; 95% CI, 0.08–0.95), and there was an increasing trend in the likelihood for surveillance between 2015 and 2018 (aRR, 1.77; 95% CI, 1.39–2.25).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.